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Abstract 
 
Diabetes is an important risk factor for cardiovascular morbidity and mortality, and atrial 
fibrillation is linked to cardiovascular complications. The prevalence of both is increasing 
and they commonly co‐ exist with a longer duration of diabetes and poorer control putting 
individuals at higher risk of atrial fibrillation. 
The complications of atrial fibrillation include heart failure and thromboembolism. There is 
an association between diabetes and atrial fibrillation and there are many theories as to the 
specific pathophysiology, including sharing similar precursors, but it is not clearly 
understood. What is understood is that the risk of developing the main consequences of atrial 
fibrillation can be reduced by treatment. Broadly speaking, this involves controlling the heart 
rhythm and/or heart rate to improve cardiac function in addition to anticoagulation. The 
development of risk stratification strategies and direct oral anticoagulants has led to safer 
anticoagulation with more individuals thought to benefit balanced against any potential risk 
of bleeding. The evidence base for treatment of atrial fibrillation includes many individuals 
with diabetes and, in this group, prevention of complications is equally as relevant. In those 
with diabetes and atrial fibrillation the evidence overwhelmingly supports a treatment 
strategy similar to that for individuals with atrial fibrillation but without diabetes. This should 
be done in addition to identifying and treating other cardiovascular risk factors. 
 
Introduction 
Diabetes is an important risk factor for cardiovascular morbidity and mortality, although the 
mechanisms are not fully understood. Similarly, atrial fibrillation (AF) is linked to 
cardiovascular complications, including thromboembolism, stroke and heart failure, and the 
prevalence of both continues to increase.1-4 
In this article, we describe recent developments in the pathophysiology, treatment and 
prevention of thromboembolic complications in individuals with AF and diabetes. 
 
Pathophysiology 
There appears to be an independent association between diabetes and AF. However, it is 
unclear if this is a direct causal one, or if there are other indirect interactions between the 
conditions, and the mechanism of this link remains uncertain.5-8 Both have common 
precursors in the form of hypertension, atherosclerosis and obesity. 
Diabetes results in defects in insulin and glucose control. This in turn can directly affect the 
myocardium of atria and ventricles. The underlying mechanism of AF may be related to 
inflammation, with biopsies of atria showing raised levels of C‐reactive protein.9 Diabetes is 
also associated with the formation of pro‐inflammatory mediators, and atrial fibrosis is 
commonly seen in AF. Left ventricular hypertrophy (LVH) is a common consequence of 
hypertension, and they are both recognised risk factors for AF. Several studies have noted an 
association with LVH and impaired glucose tolerance and insulin resistance. The duration of 
diabetes and a higher HbA1c are also linked to a greater risk of AF.
10 
Diabetes is additionally well known to have effects on the autonomic nervous system, and 
several animal studies have demonstrated that diabetic animals were more likely to develop 
AF after sympathetic nerve stimulation.11 The potential mechanisms are summarised in 
Figure 1. 
 
Figure 1 - Potential aetiological links between diabetes and atrial fibrillation 
 
Clinical consequences of atrial fibrillation, and treatment 
Atrial fibrillation can lead to cardiac dysfunction as a result of an uncontrolled heart rate and 
thromboembolic events due to the irregular rhythm. Therapeutic strategies for rate control 
include cardioversion to sinus rhythm or using medications to control rate, but the evidence 
suggests that one approach is no better than the other in terms of prognosis and, in either 
case, risk stratification and anticoagulation of those deemed to be at risk of thromboembolic 
events should be normal clinical practice. This also applies to individuals with diabetes. 
 Rate versus rhythm control 
A rate control strategy is well‐recognised within clinical guidelines.12, 13 There is little 
evidence supporting the use of one agent over another in diabetes as most trials assessing 
their efficacy do not assess outcomes in diabetes and have small numbers. 
Traditionally, rate control was achieved using digoxin; however, it has been established that, 
during exercise or in those with high sympathetic tone, digoxin is less effective.14, 15 More 
recently, beta‐blockers and non‐dihydropyridine calcium channel blockers (NCCBs) have 
been shown to be more effective than digoxin. The AFFIRM trial also suggested beta‐
blockers had a higher success rate for achieving rate control than NCCBs with or without 
digoxin.16 However, this was disputed by another trial, which suggested NCCBs were 
superior.17 The choice of agent is often influenced by the presence of left ventricular 
dysfunction or a risk of bronchospasm. The use of amiodarone for rate control is largely 
isolated to the acute setting in unstable patients, and not recommended as a long‐term option. 
There are no trials assessing the efficacy of one rate control strategy over another in those 
with diabetes. 
Rhythm control can be obtained via a variety of methods. Electrical cardioversion is a well‐
recognised technique, which has been reported to have a success rate of 90% in achieving 
return of sinus rhythm.18 However, many will develop AF again within a year.18 In one small 
retrospective study assessing the success of electrical cardioversion in those with diabetes 
against those without, diabetes and length of time in AF were independent risk factors for 
failure of electrical cardioversion.19 However, this may have been influenced by the presence 
of greater comorbidity in those with diabetes, as more were dyslipidaemic and hypertensive. 
Additionally, a raised body mass index (BMI) is known to influence the success of electrical 
cardioversion.20 
Chemical cardioversion may be achieved using anti‐arrhythmic medications such as 
amiodarone and flecainide. To the best of our knowledge, there are no studies assessing the 
efficacy of these drugs in those with diabetes. This may be in part due to the increased risk of 
arrhythmia in patients with structural heart disease, and the greater prevalence of those with 
diabetes. 
Pulmonary vein isolation and ablation also now play a key role in the management of AF in 
many patients with paroxysmal and persistent AF which is resistant to conventional anti‐
arrhythmic drug therapy.12 There is limited evidence for its use in diabetes, with trials 
involving small numbers of patients. 
A recent review of the evidence (n = 1464) suggested that ablation in diabetes was both safe 
and effective.21 Meta‐regression analysis found that increased age, BMI and HbA1c were 
associated with higher rates of recurrence of AF. Additionally, the need for redo ablations 
was more common in patients with diabetes. There is a suggestion that, due to the greater 
numbers of comorbidities in patients with diabetes, there is a higher procedural risk 
associated with ablation in this population. One study found more bleeding events in patients 
with diabetes when directly compared with those without.22 However, a study in Germany 
assessing periprocedural risks in patients undergoing ablation for AF and atrial flutter (n = 
8175) in patients with and without diabetes found that there was no significant difference 
between the groups in periprocedural or in‐hospital complications.23 As before, the group 
with diabetes were older, and had more comorbidities, although they did not have more redo 
procedures, as previously described. Additionally, a meta‐analysis of catheter ablation in 
those with diabetes found the overall risk of procedural complications to be 3.5%, which was 
equivalent to the general population.21 Longer‐term efficacy of ablation for AF in patients 
with diabetes appears to be comparable with those without diabetes; however, further study is 
needed to assess both safety and long‐term efficacy. 
 
Thromboprophylaxis 
 
Risk stratification 
There are several risk stratification models available for use to attempt to predict the risk of 
complications in patients with AF. These include CHA2DS2‐VASc and the Framingham 
schema.2 The CHADS2 risk score was previously used in guidelines due to its practicality and 
relative accuracy.12 However, it classifies a large proportion of patients to ‘intermediate risk’, 
and has a relatively modest C‐statistic score of anywhere from 0.62–0.81 (over 0.8 being 
considered a strong model).24, 25 The Framingham schema is not widely used due to its 
complexity. More recently, there has been a shift from identifying high‐risk patients, to 
determining which patients are low risk and therefore do not require anticoagulation. This has 
at least in part been influenced by the availability of a number of alternative oral 
anticoagulants, and the identification of new and less well‐defined risk factors for stroke. 
This shift in focus has resulted in the development of the CHA2DS2‐VASc scoring 
system.26This includes the well‐recognised risk factors for stroke including hypertension, 
diabetes, congestive heart failure and previous stroke, and gives increased weighting to 
increasing age. It incorporates a weighting for vascular disease, both peripheral and coronary, 
as well as being female to reflect more recent evidence. This new schema was validated using 
data from the European Heart Survey, and was found to have a C‐statistic of 0.61, second 
only to the more‐complex Framingham study which scored 0.64. 
The risk stratification models are shown in Table 1. 
Table 1 Risk scores in atrial fibrillation and the maximum points given for each comorbidity 
CHADS2 CHA2DS2‐VASc HAS‐BLED 
Congestive heart failure 1 Congestive heart failure 1 Hypertension 1 
Hypertension 1 Hypertension 1 Abnormal liver/renal function 2 
Age > 75 years 1 Age ≥ 75 years 2 Stroke 1 
Diabetes 1 Diabetes 1 Bleeding 1 
Stroke/TIA 2 Vascular disease 2 Labile INR 1 
CHADS2 CHA2DS2‐VASc HAS‐BLED 
– – Stroke/TIA 1 Age ≥ 65 years 1 
– – Age 65–74 years 1 Drugs/alcohol 2 
– – Female 1 – – 
 
 
One of the reasons for further refining the risk stratification in AF is the risk of bleeding with 
oral anticoagulation. This, in combination with an intermediate risk of stroke, can make 
decision making regarding anticoagulation challenging for medical practitioners. The HAS‐
BLED (hypertension, abnormal liver/renal function, stroke, bleeding history, labile INR, 
elderly [≥65 years], drugs) score was developed to further assist this decision making. When 
validated, using the European Heart Survey, it gave a C‐statistic of 0.72 in the whole 
population.27 
There is still some debate about the role of anticoagulation in the group of patients who fall 
into the CHA2DS2‐VASc score of 1 and the score of 1 non‐gender‐related score category. A 
recent meta‐analysis of the current evidence found there was a high degree of heterogeneity, 
and recommended the decision on anticoagulation be made based on individual patient 
characteristics.28 However, in a recent study (n = 8962) patients in AF with a score of 1 non‐
gender‐related CHA2DS2‐VASc risk factor were found to have a net clinical benefit when 
anticoagulated.29 The absolute risk at each score is shown in Table 2. 
Table 2 Absolute risk associated with risk scores for stroke and bleeding  
CHA2DS2‐VASc risk HAS‐BLED risk 
1 1.3% 1 3.4% 
2 2.2% 2 4.1% 
3 3.2% 3 5.8% 
4 4.0% 4 8.9% 
5 7.2% 5 9.1% 
6 9.7% >5 >10% 
7 11.2% – – 
CHA2DS2‐VASc risk HAS‐BLED risk 
8 10.8% – – 
9 12.2% – – 
 
 
Evidence for direct oral anticoagulants 
The management of AF changed with the introduction of direct oral anticoagulant (OAC) 
medications, and alternative therapies including left‐atrial ablation and left‐atrial appendage 
closure. The OAC medications currently licensed for use in AF are dabigatran (direct 
thrombin inhibitor), apixaban, rivaroxaban and edoxaban (factor Xa inhibitors), and these 
have begun to replace warfarin (vitamin K antagonist) in routine clinical practice. 
Table 3 summarises the evidence for direct OAC use. 
Table 3 Summary of evidence for direct oral anticoagulants 
Direct oral 
anticoagulants 
Compared to warfarin Percentage with 
diabetes 
Relative risk of 
stroke 
Relative risk of 
bleeding 
Dabigatran 110 mg 0.91 0.8 23% 
Dabigatran 150 mg 0.66 1.16 23% 
Rivaroxaban 0.79 1.03 40% 
Apixaban 0.79 0.69 25% 
Edoxaban 30 mg 1.07 0.47 36% 
Edoxaban 60 mg 0.79 0.8 36% 
 
The RE‐LY (Randomised evaluation of long‐term anticoagulation therapy) trial (n = 18 113) 
was a non‐inferiority trial looking at the efficacy and safety of dabigatran at two doses 
compared to warfarin (target INR 2.0–3.0).30 Rates of the primary outcome of stroke and 
thromboembolism were 1.69% per year in the warfarin group, as compared with 1.53% per 
year in the group that received 110 mg of dabigatran (relative risk with dabigatran 0.91; 95% 
confidence interval [CI] 0.74–1.11; p < 0.001 for non‐inferiority) and 1.11% per year in the 
group that received 150 mg of dabigatran (relative risk 0.66; 95% CI 0.53–0.82; p < 0.001 for 
superiority). The rate of major bleeding was 3.36% per year in the warfarin group, as 
compared with 2.71% per year in the group receiving 110 mg of dabigatran (p = 0.003) and 
3.11% per year in the group receiving 150 mg of dabigatran (p = 0.31). Around 23% of 
patients in each treatment arm of the study had diabetes. Although the trial achieved its aim 
by showing non‐inferiority to warfarin, there was a trend to better outcomes with both doses 
of dabigatran. 
The ROCKET‐AF (Rivaroxaban once daily oral direct factor Xa inhibition compared with 
vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) study 
(n = 14 264) was a double‐blind, non‐inferiority trial looking at the safety and efficacy of 
rivaroxaban 20 mg daily versus warfarin.31 The primary endpoint of non‐inferiority was 
achieved (hazard ratio in the rivaroxaban group 0.79; 95% CI 0.66–0.96; p < 0.001 for non‐
inferiority). Major and non‐major clinically relevant bleeding were similar in each group 
(hazard ratio 1.03; 95% CI 0.96–1.11; p = 0.44), but there was a trend toward less intracranial 
bleeding in rivaroxaban. Around 40% of patients had diabetes in the trial, and rivaroxaban 
was as effective as warfarin in preventing thromboembolic events in these patients, with no 
difference in the number of bleeding events. 
The ARISTOTLE (Apixaban for reduction in stroke and other thromboembolic events in 
atrial fibrillation) trial (n = 18 201) was a non‐inferiority trial looking at the safety and 
efficacy of apixaban at a dose of 5 mg twice‐daily versus warfarin (target INR 2.0–3.0) in 
patients with AF and at least one additional risk factor.32 In addition to being non‐inferior to 
warfarin (hazard ratio with apixaban 0.79; 95% CI 0.66–0.95; p < 0.001 for non‐inferiority), 
as a secondary endpoint apixaban was superior to warfarin in reducing rates of stroke or 
systemic embolism (p = 0.01), and the rate of major bleeding was 2.13% per year in the 
apixaban group, as compared with 3.09% per year in the warfarin group (hazard ratio 0.69; 
95% CI 0.60–0.80; p < 0.001). Around 25% of patients in ARISTOTLE had diabetes. While 
the primary outcome was consistent in this subgroup, risk of bleeding was higher compared 
to those without diabetes mellitus, but with no greater risk than warfarin. 
The ENGAGE AF‐TIMI 48 trial (n = 21 105) was a non‐inferiority trial looking at the 
efficacy and safety of edoxaban at two doses compared to warfarin (target INR 2.0–
3.0).33 Rates of the primary outcome of stroke and thromboembolism were 1.5% per year in 
the warfarin group, as compared with 1.18% per year in the group that received 60 mg 
edoxaban (hazard ratio 0.79; 97.5% CI 0.63–0.99; p < 0.001 for non‐inferiority) and 1.61% 
per year in the group that received 30 mg of edoxaban (hazard ratio 1.07; 97.5% CI 0.87–
1.31; p = 0.005 for non‐inferiority). The rate of major bleeding was 3.43% per year in the 
warfarin group, as compared with 2.75% per year in the group receiving 60 mg of edoxaban 
(hazard ratio 0.80; 95% CI 0.71–0.91; p < 0.001) and 1.61% per year in the group receiving 
30 mg of edoxaban (hazard ratio 0.47; 95% CI 0.41–0.55; p < 0.001). Around 36% of 
patients in each treatment arm of the study had diabetes with similar results in terms of 
outcomes. Although the trial achieved its aim by showing non‐inferiority to warfarin at both 
doses, there was a trend to better outcomes with the higher 60 mg dose of edoxaban. 
An alternative management option in patients who are unable to be anticoagulated is 
percutaneous left‐atrial appendage closure. This was found in PROTECT AF (Watchman left 
atrial appendage system for embolic protection in patients with atrial fibrillation) which was a 
non‐inferiority trial (n = 707) looking at the safety and efficacy of percutaneous catheter left‐
atrial appendage and closure with filter device (Watchman) versus conventional 
anticoagulation with warfarin.34 It was shown to be non‐inferior (relative risk 0.71; 95% CI 
0.44–1.30 per year), which met the criteria for non‐inferiority (probability of non‐inferiority 
>0.999). However, there was no subgroup analysis done on patients with diabetes, and its 
application in this group of patients requires further study. 
 
Conclusion 
There is a well‐recognised relationship between AF and diabetes. However, this relationship 
is one that remains poorly understood. There are numerous risk stratification scores available, 
and the CHA2DS2‐VASc scoring system is a robust method of categorising low‐risk patients. 
However, there remains a minority group of ‘intermediate‐risk’ patients in whom the decision 
about whether to anticoagulate is not well‐defined. 
Anticoagulation with the newer generation of OAC medications is safe and effective. 
Apixaban was found to have a higher number of bleeding events in patients with diabetes 
when compared with those without diabetes, but was still comparable with warfarin. There is 
a similar trend seen in a meta‐analysis of three trials (dabigatran, rivaroxaban, apixaban) for 
those with diabetes, but it did not outweigh the benefits of stroke risk reduction.35 
Left‐atrial ablation and appendage closure offer alternative therapies for the treatment of AF. 
Ablation has been proven to give good symptomatic and rhythm results; however, in patients 
with diabetes, further study is required to better define their role in the management of AF. 
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